IGF::OT::IGF R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

IGF::OT::IGF R

• 批准号: 9148277
• 负责人: Fahd Albinali
• 金额: $ 149.93万
• 依托单位: EVERY FIT, INC.
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-15 至 2017-09-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9148277
• 关键词: Adoption; Basic Science; Behavioral; Behavioral Research; Cancer Control; Cancer Survivor; Cellular Phone; Cessation of life; Chronic Disease; Clinical; Clinical Research; Computer software; Diagnostic; Division of Cancer Control and Population Sciences; Evaluation; Health; Health Technology; Incidence; Intervention; Malignant Neoplasms; Medical; Mission; Monitor; Phase; Quality of life; Risk; Risk Factors; Small Business Innovation Research Grant; Technology; Treatment Efficacy; Validation; Wireless Technology; cancer care; cancer prevention; clinical practice; cost; follow-up; improved; innovation; lifestyle intervention; research and development; screening; sensor; tool

SBIR Direct-to-Phase II Topic 340 encourages validation of mobile/wireless tools to support cancer prevention & control in clinical behavioral applications. Technologies may include wireless sensors, smartphone applications, behavioral analytics and decision support software or integrated platforms for health assessment, monitoring or intervention delivery. This topic is intended to clinically validate recently developed but not yet validated tools, in order to expand evidence of commercial potential and value.

SBIR Direct-to-Phase II Topic 340鼓励验证移动的/无线工具，以支持临床行为应用中的癌症预防和控制。技术可能包括无线传感器、智能手机应用程序、行为分析和决策支持软件或用于健康评估、监测或干预交付的集成平台。本主题旨在临床验证最近开发但尚未验证的工具，以扩大商业潜力和价值的证据。